MTNB Matinas BioPharma Holdings Inc

Price (delayed)

$0.175

Market cap

$2.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$1.82M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 11
Highlights
Matinas BioPharma Holdings's debt has shrunk by 100% YoY and by 99% QoQ
The EPS has soared by 70% YoY and by 41% from the previous quarter
The company's quick ratio has shrunk by 84% YoY and by 48% QoQ
The company's equity has shrunk by 77% YoY and by 40% QoQ

Key stats

What are the main financial stats of MTNB

MTNB stock price

How has the Matinas BioPharma Holdings stock price performed over time
Intraday
-1.13%
1 week
6%
1 month
-11.97%
1 year
-90.98%
YTD
-70.14%
QTD
-71.41%

Financial performance

How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.88M
Net income
-$6.69M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 66% YoY and by 37% QoQ
The operating income has soared by 58% YoY

Price vs fundamentals

How does MTNB's price correlate with its fundamentals

Growth

What is Matinas BioPharma Holdings's growth rate over time

Valuation

What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
0.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 70% YoY and by 41% from the previous quarter
The company's equity has shrunk by 77% YoY and by 40% QoQ
The stock's price to book (P/B) is 73% less than its 5-year quarterly average of 2.3 and 55% less than its last 4 quarters average of 1.4

Efficiency

How efficient is Matinas BioPharma Holdings business performance
Matinas BioPharma Holdings's ROIC has increased by 25% YoY and by 14% from the previous quarter
The return on assets is up by 19% year-on-year and by 15% since the previous quarter
The ROE is up by 14% year-on-year and by 11% since the previous quarter

Dividends

What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MTNB.

Financial health

How did Matinas BioPharma Holdings financials performed over time
Matinas BioPharma Holdings's total assets is 112% higher than its total liabilities
The company's quick ratio has shrunk by 84% YoY and by 48% QoQ
MTNB's current ratio has dropped by 79% year-on-year and by 36% since the previous quarter
Matinas BioPharma Holdings's debt is 100% lower than its equity
Matinas BioPharma Holdings's debt has shrunk by 100% YoY and by 99% QoQ
The company's debt to equity has shrunk by 100% QoQ and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.